South State Boosted Its Dow Chem Company (DOW) Position; Array Biopharma (ARRY) Sentiment Is 1.3

June 22, 2017 - By Peter Erickson

South State Corp increased Dow Chem Company (DOW) stake by 48.35% reported in 2016Q4 SEC filing. South State Corp acquired 10,393 shares as Dow Chem Company (DOW)’s stock rose 0.05%. The South State Corp holds 31,887 shares with $1.83 million value, up from 21,494 last quarter. Dow Chem Company now has $76.28 billion valuation. The stock rose 0.24% or $0.15 reaching $63.83 per share. About 200 shares traded. Dow Chemical Co (NYSE:DOW) has risen 20.72% since June 22, 2016 and is uptrending. It has outperformed by 4.02% the S&P500.

Array BioPharma Inc. is a biopharmaceutical firm focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The company has market cap of $1.66 billion. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib . It currently has negative earnings. The Company’s binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC).

Since January 1, 0001, it had 0 buys, and 2 insider sales for $633,150 activity.

Ratings analysis reveals 75% of Array Biopharma’s analysts are positive. Out of 4 Wall Street analysts rating Array Biopharma, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $9.0 while the high is $13.0. The stock’s average target of $10.67 is 18.29% above today’s ($9.02) share price. ARRY was included in 4 notes of analysts from September 26, 2016. On Friday, February 3 the stock rating was downgraded by JP Morgan to “Neutral”. Piper Jaffray maintained it with “Overweight” rating and $10.0 target in Monday, September 26 report. The stock has “Buy” rating by Stifel Nicolaus on Friday, February 3. The stock has “Outperform” rating by Leerink Swann on Monday, September 26.

About 802 shares traded. Array Biopharma Inc (ARRY) has risen 176.51% since June 22, 2016 and is uptrending. It has outperformed by 159.81% the S&P500.

Redmile Group Llc holds 12.59% of its portfolio in Array Biopharma Inc for 16.62 million shares. Bvf Inc Il owns 4.99 million shares or 8.81% of their US portfolio. Moreover, First Light Asset Management Llc has 3.86% invested in the company for 1.00 million shares. The California-based Sanctuary Wealth Advisors Llc has invested 3.62% in the stock. Consonance Capital Management Lp, a New York-based fund reported 2.72 million shares.

Among 15 analysts covering The Dow Chemical Company (NYSE:DOW), 8 have Buy rating, 1 Sell and 6 Hold. Therefore 53% are positive. The Dow Chemical Company had 39 analyst reports since August 20, 2015 according to SRatingsIntel. The rating was initiated by Bernstein on Friday, September 11 with “Outperform”. The firm has “Top Pick” rating given on Friday, October 28 by RBC Capital Markets. The stock has “Outperform” rating by RBC Capital Markets on Friday, October 23. The rating was upgraded by Susquehanna on Monday, February 8 to “Positive”. The firm earned “Hold” rating on Monday, December 14 by Jefferies. The firm earned “Outperform” rating on Friday, April 29 by RBC Capital Markets. Jefferies maintained the stock with “Hold” rating in Monday, May 2 report. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, May 30 report. As per Monday, August 24, the company rating was upgraded by Zacks. The firm earned “Hold” rating on Wednesday, May 31 by Cowen & Co.

Investors sentiment increased to 1.52 in 2016 Q4. Its up 0.18, from 1.34 in 2016Q3. It increased, as 53 investors sold DOW shares while 333 reduced holdings. 128 funds opened positions while 459 raised stakes. 790.77 million shares or 7.17% more from 737.86 million shares in 2016Q3 were reported. Centurylink Inv Mngmt reported 41,497 shares stake. Peloton Wealth Strategists stated it has 57,622 shares. Nwq Inv Management Communication holds 0.74% or 958,730 shares. Janney Montgomery Scott Limited stated it has 0.28% of its portfolio in Dow Chemical Co (NYSE:DOW). South Texas Money Management Limited reported 4,384 shares. Carret Asset Management Llc invested in 27,356 shares or 0.3% of the stock. Outfitter Advsr Limited has invested 0.19% in Dow Chemical Co (NYSE:DOW). New Hampshire-based D L Carlson Group Inc has invested 0.13% in Dow Chemical Co (NYSE:DOW). Gilman Hill Asset Mngmt Lc accumulated 11,603 shares or 0.24% of the stock. Mai Capital has invested 0.16% in Dow Chemical Co (NYSE:DOW). Grantham Mayo Van Otterloo & Llc has 30,500 shares for 0.01% of their portfolio. The Illinois-based State Farm Mutual Automobile Ins Co has invested 0.46% in Dow Chemical Co (NYSE:DOW). Mayo Advisers Ltd Liability Co has 1.22% invested in Dow Chemical Co (NYSE:DOW). Alethea Management Limited Liability Company invested in 10,000 shares. Private Com Na owns 22,616 shares.